Personalized laboratory medicine: a patient-centered future approach
Open Access
- 10 July 2018
- journal article
- review article
- Published by Walter de Gruyter GmbH in Clinical Chemistry and Laboratory Medicine (CCLM)
- Vol. 56 (12) , 1981-1991
Abstract
In contrast to population-based medical decision making, which emphasizes the use of evidence-based treatment strategies for groups of patients, personalized medicine is based on optimizing treatment at the level of the individual patient. The creation of molecular profiles of individual patients was made possible by the advent of “omics” technologies, based on high throughput instrumental techniques in combination with biostatistics tools and artificial intelligence. The goal of personalized laboratory medicine is to use advanced technologies in the process of preventive, curative or palliative patient management. Personalized medicine does not rely on changes in concentration of a single molecular marker to make a therapeutic decision, but rather on changes of a profile of markers characterizing an individual patient’s status, taking into account not only the expected response to treatment of the disease but also the expected response of the patient. Such medical approach promises a more effective diagnostics with more effective and safer treatment, as well as faster recovery and restoration of health and improved cost effectiveness. The laboratory medicine profession is aware of its key role in personalized medicine, but to empower the laboratories, at least an enhancement in cooperation between disciplines within laboratory medicine will be necessary.Keywords
This publication has 48 references indexed in Scilit:
- Position paper of the EPMA and EFLM: a global vision of the consolidated promotion of an integrative medical approach to advance health careEPMA Journal, 2013
- Momentum grows to make 'personalized' medicine more 'precise'Nature Medicine, 2013
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 UpdateClinical Pharmacology & Therapeutics, 2013
- Challenges in biomarker discovery: combining expert insights with statistical analysis of complex omics dataExpert Opinion on Medical Diagnostics, 2012
- Predictive, personalized, preventive, participatory (P4) cancer medicineNature Reviews Clinical Oncology, 2011
- Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine DosingClinical Pharmacology & Therapeutics, 2011
- Mass spectrometry in newborn and metabolic screening: historical perspective and future directionsJournal of Mass Spectrometry, 2008
- Characterisation of novel defective thiopurine S-methyltransferase allelic variantsBiochemical Pharmacology, 2008
- Chromatographic Analysis of Amino and Organic Acids in Physiological Fluids to Detect Inborn Errors of MetabolismCurrent Protocols in Human Genetics, 2006
- Pharmacogenetics/genomics and personalized medicineHuman Molecular Genetics, 2005